Effect of pyridoxine supplementation on plasma oxalate concentrations in patients receiving dialysis
| Autor: | M. K. Ward, I. S. Parkinson, Charles R.V. Tomson, W. S. Sheldon, S. M. Channon, M. K. Laker |
|---|---|
| Rok vydání: | 1989 |
| Předmět: |
medicine.medical_specialty
Erythrocytes medicine.medical_treatment Clinical Biochemistry Biochemistry Oxalate Transaminase chemistry.chemical_compound Peritoneal Dialysis Continuous Ambulatory Renal Dialysis Internal medicine medicine Humans Citrate synthase Pyridoxine Deficiency Aspartate Aminotransferases Dialysis Oxalates biology Chemistry Oxalic Acid Continuous ambulatory peritoneal dialysis Pyridoxine General Medicine Endocrinology Glycine biology.protein Kidney Failure Chronic Vitamin B 6 Deficiency medicine.drug |
| Zdroj: | European Journal of Clinical Investigation. 19:201-205 |
| ISSN: | 1365-2362 0014-2972 |
| DOI: | 10.1111/j.1365-2362.1989.tb00218.x |
| Popis: | Plasma oxalate and erythrocyte glutamic oxaloacetate transaminase activity (EGOT) (an indicator of nutritional status with respect to pyridoxine) were measured in 21 patients maintained on regular continuous ambulatory peritoneal dialysis or haemodialysis before and after a 4-month period of supplementation with pyridoxine, 100 mg day-1. Prior to supplementation 10/21 patients showed subnormal EGOT activity, although the increment in activity on addition of pyridoxal-5-phosphate in vitro was within the normal range in all cases. Mean plasma oxalate was 31.5 μmol 1-1 (SEM 2.9) prior to supplementation and did not change significantly with supplementation, despite normalization of EGOT activity in all but 2/21 patients. We conclude that pyridoxine deficiency does not contribute significantly to hyperoxalaemia in patients receiving dialysis and that 100 mg of pyridoxine daily is insufficient to reduce oxalate generation by a pharmacological action on glycine transamination. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text